Kyntra Bio
KYNB
187 hedge funds and large institutions have $2.25B invested in Kyntra Bio in 2020 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 54 increasing their positions, 72 reducing their positions, and 46 closing their positions.
0.13% more ownership
Funds ownership: 2.82% → 2.94% (+0.13%)
12% less funds holding
Funds holding: 213 → 187 (-26)
15% less capital invested
Capital invested by funds: $2.63B → $2.25B (-$382M)
25% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 72
48% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 46
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
52% less call options, than puts
Call options by funds: $12M | Put options by funds: $24.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$158M |
| 2 |
Janus Henderson Group
London,
|
+$17.5M |
| 3 |
BlackRock
New York
|
+$15.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.9M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$9.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$24.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11.4M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$9.29M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$9.26M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.6M |
KYNB Hedge Fund Activity: Q1 2020 in Review
187 of the 4,546 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q1 2020, worth a combined $2.25B — down 15% from $2.63B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of KYNB and 24 opened new positions — a net loss of 22 holders — while 72 trimmed existing stakes and 54 added.
The largest buyer was Primecap Management, adding an estimated $158M. The largest seller was EcoR1 Capital, cutting an estimated $24.3M.
- 187 institutional investors held Kyntra Bio (KYNB) as of Q1 2020, down from 213 in Q4 2019.
- Funds reported $2.25B of Kyntra Bio stock for Q1 2020, down 15% quarter-over-quarter.
- 24 funds opened new Kyntra Bio positions in Q1 2020 and 46 closed out, a net change of -22 holders.
- The largest Kyntra Bio buyer in Q1 2020 was Primecap Management, an estimated $158M added.
- The largest Kyntra Bio seller in Q1 2020 was EcoR1 Capital, an estimated $24.3M sold.
Based on aggregated 13F filings for Q1 2020.